Publication

In Vivo Responses of Human A375M Melanoma to a sigma Ligand: F-18-FDG PET Imaging

Rybczynska, A. A., de Bruyn, M., K. Ramakrishnan, N., de Jong, J. R., Elsinga, P. H., Helfrich, W., Dierckx, R. A. J. O. & van Waarde, A., 1-Sep-2013, In : Journal of Nuclear Medicine. 54, 9, p. 1613-1620 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Rybczynska, A. A., de Bruyn, M., K. Ramakrishnan, N., de Jong, J. R., Elsinga, P. H., Helfrich, W., ... van Waarde, A. (2013). In Vivo Responses of Human A375M Melanoma to a sigma Ligand: F-18-FDG PET Imaging. Journal of Nuclear Medicine, 54(9), 1613-1620. https://doi.org/10.2967/jnumed.113.122655

Author

Rybczynska, Anna A. ; de Bruyn, Marco ; K. Ramakrishnan, Nisha ; de Jong, Johan R. ; Elsinga, Philip H. ; Helfrich, Wijnand ; Dierckx, Rudi A. J. O. ; van Waarde, Aren. / In Vivo Responses of Human A375M Melanoma to a sigma Ligand : F-18-FDG PET Imaging. In: Journal of Nuclear Medicine. 2013 ; Vol. 54, No. 9. pp. 1613-1620.

Harvard

Rybczynska, AA, de Bruyn, M, K. Ramakrishnan, N, de Jong, JR, Elsinga, PH, Helfrich, W, Dierckx, RAJO & van Waarde, A 2013, 'In Vivo Responses of Human A375M Melanoma to a sigma Ligand: F-18-FDG PET Imaging', Journal of Nuclear Medicine, vol. 54, no. 9, pp. 1613-1620. https://doi.org/10.2967/jnumed.113.122655

Standard

In Vivo Responses of Human A375M Melanoma to a sigma Ligand : F-18-FDG PET Imaging. / Rybczynska, Anna A.; de Bruyn, Marco; K. Ramakrishnan, Nisha; de Jong, Johan R.; Elsinga, Philip H.; Helfrich, Wijnand; Dierckx, Rudi A. J. O.; van Waarde, Aren.

In: Journal of Nuclear Medicine, Vol. 54, No. 9, 01.09.2013, p. 1613-1620.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Rybczynska AA, de Bruyn M, K. Ramakrishnan N, de Jong JR, Elsinga PH, Helfrich W et al. In Vivo Responses of Human A375M Melanoma to a sigma Ligand: F-18-FDG PET Imaging. Journal of Nuclear Medicine. 2013 Sep 1;54(9):1613-1620. https://doi.org/10.2967/jnumed.113.122655


BibTeX

@article{81575954738147f5b61ec844e0055056,
title = "In Vivo Responses of Human A375M Melanoma to a sigma Ligand: F-18-FDG PET Imaging",
abstract = "sigma-ligands can kill tumor cells. Previously we have shown that a short in vitro incubation of C6 tumor cells with sigma-ligands (24 h) results in a dose-dependent increase of cellular F-18-FDG uptake and that the magnitude of this increase is predictive of subsequent cell death. Here, we aimed to assess whether the sigma-ligand rimcazole inhibits growth of A375M melanoma xenografts in nude mice and whether rimcazole treatment changes F-18-FDG uptake in vivo. Methods: Athymic mice were inoculated with A375M melanoma cells. After 2 wk, tumors had reached a size of 41 +/- 6 mm(3). We then started a 14-d treatment schedule with daily drug dosing. Control animals were injected with water and treated animals with rimcazole (26 mg/kg) in water. Three small-animal PET scans with F-18-FDG were obtained: on days 0, 7, and 14 of treatment. After the last scan, animals were terminated, and a biodistribution study was performed. Results: Rimcazole treatment resulted in a greater than 4-fold reduction of tumor weight in comparison to controls at day 14 (100 +/- 26 vs. 436 +/- 117 mg, respectively, P <0.03). Treatment did not affect the levels of (nonradioactive) glucose in blood, sigma-1 and sigma-2 receptor expression in the tumor, animal weight, behavior, or appearance. Antitumor activity of rimcazole was accompanied by a transient increase of the tumor uptake of F-18-FDG (measured at day 7). Significant increases of F-18-FDG uptake at day 14 were observed in the liver and pancreas. Conclusion: Rimcazole strongly inhibited the growth of A375M melanoma xenografts. This growth inhibition is accompanied by an early increase of F-18-FDG uptake in the tumor.",
keywords = "sigma receptors, rimcazole, melanoma, FDG PET, antitumor effect, TUMOR-CELL-LINES, BREAST-CANCER, MALIGNANT-MELANOMA, RECEPTOR LIGANDS, BINDING-SITE, GUINEA-PIG, PC12 CELLS, BCL-XS, HALOPERIDOL, GROWTH",
author = "Rybczynska, {Anna A.} and {de Bruyn}, Marco and {K. Ramakrishnan}, Nisha and {de Jong}, {Johan R.} and Elsinga, {Philip H.} and Wijnand Helfrich and Dierckx, {Rudi A. J. O.} and {van Waarde}, Aren",
year = "2013",
month = "9",
day = "1",
doi = "10.2967/jnumed.113.122655",
language = "English",
volume = "54",
pages = "1613--1620",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "SOC NUCLEAR MEDICINE INC",
number = "9",

}

RIS

TY - JOUR

T1 - In Vivo Responses of Human A375M Melanoma to a sigma Ligand

T2 - F-18-FDG PET Imaging

AU - Rybczynska, Anna A.

AU - de Bruyn, Marco

AU - K. Ramakrishnan, Nisha

AU - de Jong, Johan R.

AU - Elsinga, Philip H.

AU - Helfrich, Wijnand

AU - Dierckx, Rudi A. J. O.

AU - van Waarde, Aren

PY - 2013/9/1

Y1 - 2013/9/1

N2 - sigma-ligands can kill tumor cells. Previously we have shown that a short in vitro incubation of C6 tumor cells with sigma-ligands (24 h) results in a dose-dependent increase of cellular F-18-FDG uptake and that the magnitude of this increase is predictive of subsequent cell death. Here, we aimed to assess whether the sigma-ligand rimcazole inhibits growth of A375M melanoma xenografts in nude mice and whether rimcazole treatment changes F-18-FDG uptake in vivo. Methods: Athymic mice were inoculated with A375M melanoma cells. After 2 wk, tumors had reached a size of 41 +/- 6 mm(3). We then started a 14-d treatment schedule with daily drug dosing. Control animals were injected with water and treated animals with rimcazole (26 mg/kg) in water. Three small-animal PET scans with F-18-FDG were obtained: on days 0, 7, and 14 of treatment. After the last scan, animals were terminated, and a biodistribution study was performed. Results: Rimcazole treatment resulted in a greater than 4-fold reduction of tumor weight in comparison to controls at day 14 (100 +/- 26 vs. 436 +/- 117 mg, respectively, P <0.03). Treatment did not affect the levels of (nonradioactive) glucose in blood, sigma-1 and sigma-2 receptor expression in the tumor, animal weight, behavior, or appearance. Antitumor activity of rimcazole was accompanied by a transient increase of the tumor uptake of F-18-FDG (measured at day 7). Significant increases of F-18-FDG uptake at day 14 were observed in the liver and pancreas. Conclusion: Rimcazole strongly inhibited the growth of A375M melanoma xenografts. This growth inhibition is accompanied by an early increase of F-18-FDG uptake in the tumor.

AB - sigma-ligands can kill tumor cells. Previously we have shown that a short in vitro incubation of C6 tumor cells with sigma-ligands (24 h) results in a dose-dependent increase of cellular F-18-FDG uptake and that the magnitude of this increase is predictive of subsequent cell death. Here, we aimed to assess whether the sigma-ligand rimcazole inhibits growth of A375M melanoma xenografts in nude mice and whether rimcazole treatment changes F-18-FDG uptake in vivo. Methods: Athymic mice were inoculated with A375M melanoma cells. After 2 wk, tumors had reached a size of 41 +/- 6 mm(3). We then started a 14-d treatment schedule with daily drug dosing. Control animals were injected with water and treated animals with rimcazole (26 mg/kg) in water. Three small-animal PET scans with F-18-FDG were obtained: on days 0, 7, and 14 of treatment. After the last scan, animals were terminated, and a biodistribution study was performed. Results: Rimcazole treatment resulted in a greater than 4-fold reduction of tumor weight in comparison to controls at day 14 (100 +/- 26 vs. 436 +/- 117 mg, respectively, P <0.03). Treatment did not affect the levels of (nonradioactive) glucose in blood, sigma-1 and sigma-2 receptor expression in the tumor, animal weight, behavior, or appearance. Antitumor activity of rimcazole was accompanied by a transient increase of the tumor uptake of F-18-FDG (measured at day 7). Significant increases of F-18-FDG uptake at day 14 were observed in the liver and pancreas. Conclusion: Rimcazole strongly inhibited the growth of A375M melanoma xenografts. This growth inhibition is accompanied by an early increase of F-18-FDG uptake in the tumor.

KW - sigma receptors

KW - rimcazole

KW - melanoma

KW - FDG PET

KW - antitumor effect

KW - TUMOR-CELL-LINES

KW - BREAST-CANCER

KW - MALIGNANT-MELANOMA

KW - RECEPTOR LIGANDS

KW - BINDING-SITE

KW - GUINEA-PIG

KW - PC12 CELLS

KW - BCL-XS

KW - HALOPERIDOL

KW - GROWTH

U2 - 10.2967/jnumed.113.122655

DO - 10.2967/jnumed.113.122655

M3 - Article

VL - 54

SP - 1613

EP - 1620

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -

ID: 5952096